The role of PET/CT in the diagnosis and response assessment in patients with multiple myeloma
https://doi.org/10.17650/1818-8346-2021-16-3-33-39
Abstract
A brief review focuses on the radiation diagnostics methods used in the examination of patients with myeloma and plasmacytoma. Modern imaging techniques, such as positron emission tomography combined with computed tomography (PET/CT) and magnetic resonance imaging, facilitate diagnosis and allow assessing the extent of the process and efficiency of treatment performed. Moreover, each of these methods has its own advantages and disadvantages. The most promising is PET/CT, which has sensitivity and specificity comparable to magnetic resonance imaging, while having unique advantages.
About the Authors
A. E. Pankratov
PET-Technology Balashikha
Russian Federation
Russian Federation
Aleksandr E. Pankratov
6B Karbysheva St., Balashikha, Moscow region 143900
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3–9. DOI: 10.1038/leu.2008.291.
2. Mendeleeva L.P., Votyakova O.M., Rekhtina I.G. et al. Multiple myeloma. Russian Clinical Guidelines. Moscow, 2020. Available at: https://cr.minzdrav.gov.ru/schema/144_1. (In Russ.).
3. Durie B.G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006;42(11):1539–43. DOI: 10.1016/j.ejca.2005.11.037.
4. Dimopoulos M., Kyle R., Fermand J.P. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117(18):4701–5. DOI: 10.1182/blood-2010-10-299529.
5. Lütje S., de Rooy J.W., Croockewit S. et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009;88(12):1161–8. DOI: 10.1007/s00277-009-0829-0.
6. Dimopoulos M., Terpos E., Comenzo R. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545–56. DOI: 10.1038/leu.2009.89.
7. D’Sa S., Abildgaard N., Tighe J. et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137(1):49–63. DOI: 10.1111/j.1365-2141.2007.06491.x.
8. Zamagni E., Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012;159(5): 499–513. DOI: 10.1111/bjh.12007.
9. Cavo M., Terpos E., Nanni C. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18(4):e206–17. DOI: 10.1016/S1470-2045(17)30189-4.
10. Sachpekidis C., Mai E.K., Goldschmidt H. et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med 2015;40(6):e300–7. DOI: 10.1097/RLU.0000000000000773.
11. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl 1):11S–20S. DOI: 10.2967/jnumed.108.057182.
12. Caers J., Withofs N., Hillengass J. et al. The role of positron emission tomographycomputed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 2014;99(4):629–37. DOI: 10.3324/haematol.2013.091918.
13. Bartel T.B., Haessler J., Brown T.L. et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114(10):2068–76. DOI: 10.1182/blood-2009-03-213280.
14. Davies F.E., Rosenthal A., Rasche L. et al. Treatment to suppression of focal lesions on positron emission tomographycomputed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica 2018;103(6):1047–53. DOI: 10.3324/haematol.2017.177139.
Review
For citations:
Pankratov A.E., Zeynalova P.A. The role of PET/CT in the diagnosis and response assessment in patients with multiple myeloma. Oncohematology. 2021;16(3):33-39. (In Russ.) https://doi.org/10.17650/1818-8346-2021-16-3-33-39
Views:
9779
Email this article 